19-21 January, 2012
2012 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO), San Francisco, USA |
|
Investigation of the HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC): Clinical Data from the Phase I/II SHELTER Study |
10-13 December, 2011
ASH - Annual Meeting of the American Society of Hematology, San Diego, USA |
|
Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma |
7-8 December, 2011
2nd World Epigentic Summit, Munich, Germany |
|
Resminostat: A Novel Oral Histone Deacetylase Inhibitor in Phase II Clinical Development |
22-25 June, 2011
ESMO 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain |
|
Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC)
A Phase I/II Study of Resminostat, an Oral Histone Deacetylase Inhibitor (HDACi), in Combination with FOLFIRI as Second-Line Treatment in KRAS Mutated Colorectal Cancer (CRC) patients - the SHORE Study |
20-21 January, 2011
2011 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO), San Francisco, USA |
|
Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC) |
4-7 December, 2010
ASH, Orlando, USA |
|
Resminostat in Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) inhibitor |
16-19 November, 2010
22nd EORTC-NCI-AACR Symposium, Berlin, Germany |
|
Clinical Phase II Development of Resminostat, a Novel HDAC Inhibitor
Centralised Analysis of Phase I ECG Dataset of Resminostat, a New Oral Histone Deacetylase Inhibitor (HDACi) |
23-26 October, 2010
International Symposium on Hodgkin Lymphoma, Köln, Germany |
|
Initial Results from the SAPHIRE Study: A Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients |
17 September, 2010
“Viszeralmedizin 2010” Symposium, Stuttgart, Germany |
|
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) - the SHELTER study |
2010
Br J Haematol. 2010 May;149(4):518-28 |
|
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. |
29 May - 2 June, 2009
ASCO, Orlando, Florida, USA |
|
A first-in-human Phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with solid tumors |
